FGF2 isoforms play distinct roles in tubular epithelial-to-mesenchymal transition in diabetic nephropathy.

[1]  G. Bakris,et al.  Molecular Mechanisms and Therapeutic Targets for Diabetic Kidney Disease. , 2022, Kidney international.

[2]  Hong Xiang,et al.  Research progress of endothelial‐mesenchymal transition in diabetic kidney disease , 2022, Journal of cellular and molecular medicine.

[3]  G. Ji,et al.  New progress in drugs treatment of diabetic kidney disease. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Mingjun Shi,et al.  Identification of YAP1 as a novel downstream effector of the FGF2/STAT3 pathway in the pathogenesis of renal tubulointerstitial fibrosis , 2021, Journal of cellular physiology.

[5]  M. Saint-Geniez,et al.  EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration , 2020, International journal of molecular sciences.

[6]  E. Kardami,et al.  Low and High Molecular Weight FGF-2 Have Differential Effects on Astrocyte Proliferation, but Are Both Protective Against Aβ-Induced Cytotoxicity , 2020, Frontiers in Molecular Neuroscience.

[7]  J. Chen,et al.  Bleomycin induces epithelial-to-mesenchymal transition via bFGF/PI3K/ESRP1 signaling in pulmonary fibrosis , 2019, Bioscience reports.

[8]  J. Bonventre,et al.  Cellular Senescence in the Kidney. , 2019, Journal of the American Society of Nephrology : JASN.

[9]  T. Doetschman,et al.  Ablation of low‐molecular‐weight FGF2 isoform accelerates murine osteoarthritis while loss of high‐molecular‐weight FGF2 isoforms offers protection , 2018, Journal of cellular physiology.

[10]  Bernadette A. Thomas.  The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps , 2019, Current Diabetes Reports.

[11]  Peter A. Todd,et al.  pat‐geom: A software package for the analysis of animal patterns , 2019, Methods in Ecology and Evolution.

[12]  Cheng Yang,et al.  Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury , 2018, Cell Death & Disease.

[13]  J. Melendez,et al.  Senescence in chronic allograft nephropathy. , 2018, American journal of physiology. Renal physiology.

[14]  N. Dulin,et al.  Fibroblast growth factor 2 decreases bleomycin‐induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation , 2018, The Journal of pathology.

[15]  Liping Xiao,et al.  FGF23 Regulates Wnt/β-Catenin Signaling-Mediated Osteoarthritis in Mice Overexpressing High-Molecular-Weight FGF2. , 2018, Endocrinology.

[16]  M. Hurley,et al.  Fibroblast Growth Factor 2 and Its Receptors in Bone Biology and Disease , 2018, Journal of the Endocrine Society.

[17]  G. Costa,et al.  Ten-year comparative analysis of incidence, prognosis, and associated factors for dialysis and renal transplantation in type 1 and type 2 diabetes versus non-diabetes , 2018, Acta Diabetologica.

[18]  Quanbin Zhang,et al.  Low molecular weight fucoidan and its fractions inhibit renal epithelial mesenchymal transition induced by TGF-β1 or FGF-2. , 2017, International journal of biological macromolecules.

[19]  W. Liming,et al.  Metformin reverses bFGF-induced epithelial-mesenchymal transition in HCC cells , 2017, Oncotarget.

[20]  Liping Xiao,et al.  Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice , 2017, Endocrinology.

[21]  Liping Xiao,et al.  FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice , 2017, Journal of cellular physiology.

[22]  Liping Xiao,et al.  FGF2 High Molecular Weight Isoforms Contribute to Osteoarthropathy in Male Mice. , 2016, Endocrinology.

[23]  Liping Xiao,et al.  FGFR Inhibitor Ameliorates Hypophosphatemia and Impaired Engrailed‐1/Wnt Signaling in FGF2 High Molecular Weight Isoform Transgenic Mice , 2016, Journal of cellular biochemistry.

[24]  Kebin Hu,et al.  Inhibition of Wnt/β-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-β1 and FGF-2. , 2016, Experimental and molecular pathology.

[25]  L. Magnelli,et al.  Roles of different IRES-dependent FGF2 isoforms in the acquisition of the major aggressive features of human metastatic melanoma , 2016, Journal of Molecular Medicine.

[26]  S. Weiss,et al.  Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease , 2015, Nature Medicine.

[27]  R. Kalluri,et al.  Epithelial to Mesenchymal Transition induces cell cycle arrest and parenchymal damage in renal fibrosis , 2015, Nature Medicine.

[28]  Hua-Qin Wang,et al.  Implication of Bcl-2-associated athanogene 3 in fibroblast growth factor-2-mediated epithelial–mesenchymal transition in renal epithelial cells , 2015, Experimental biology and medicine.

[29]  R. Mecham,et al.  Fibroblast growth factor 2 is required for epithelial recovery, but not for pulmonary fibrosis, in response to bleomycin. , 2015, American journal of respiratory cell and molecular biology.

[30]  Youhua Liu,et al.  Klotho suppresses renal tubulo‐interstitial fibrosis by controlling basic fibroblast growth factor‐2 signalling , 2014, The Journal of pathology.

[31]  T. Doetschman,et al.  Knockout of Nuclear High Molecular Weight FGF2 Isoforms in Mice Modulates Bone and Phosphate Homeostasis* , 2014, The Journal of Biological Chemistry.

[32]  Jun Du,et al.  AKT/GSK-3β regulates stability and transcription of snail which is crucial for bFGF-induced epithelial-mesenchymal transition of prostate cancer cells. , 2014, Biochimica et biophysica acta.

[33]  N. Lemoine,et al.  Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion , 2014, EMBO molecular medicine.

[34]  L. Charles,et al.  Fibroblast growth factor-2 isoform (low molecular weight/18 kDa) overexpression in preosteoblast cells promotes bone regeneration in critical size calvarial defects in male mice. , 2014, Endocrinology.

[35]  G. Gambaro,et al.  Heparanase and Syndecan-1 Interplay Orchestrates Fibroblast Growth Factor-2-induced Epithelial-Mesenchymal Transition in Renal Tubular Cells , 2011, The Journal of Biological Chemistry.

[36]  Youhua Liu.  New insights into epithelial-mesenchymal transition in kidney fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.

[37]  Liping Xiao,et al.  Nuclear Isoforms of Fibroblast Growth Factor 2 Are Novel Inducers of Hypophosphatemia via Modulation of FGF23 and KLOTHO* , 2009, The Journal of Biological Chemistry.

[38]  J. Saklatvala,et al.  Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. , 2009, Arthritis and rheumatism.

[39]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[40]  M. Rastaldi,et al.  Role of basic fibroblast growth factor (FGF-2) in diabetic nephropathy and mechanisms of its induction by hyperglycemia in human renal fibroblasts. , 2009, American journal of physiology. Renal physiology.

[41]  P. Claus,et al.  Fibroblast growth factor receptor-1 (FGFR1) nuclear dynamics reveal a novel mechanism in transcription control. , 2009, Molecular biology of the cell.

[42]  T. Doetschman,et al.  Exported 18-kDa Isoform of Fibroblast Growth Factor-2 Is a Critical Determinant of Bone Mass in Mice* , 2009, Journal of Biological Chemistry.

[43]  W. Nickel.  Unconventional secretion: an extracellular trap for export of fibroblast growth factor 2 , 2007, Journal of Cell Science.

[44]  I. Ono,et al.  Basic fibroblast growth factor in an artificial dermis promotes apoptosis and inhibits expression of α‐smooth muscle actin, leading to reduction of wound contraction , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[45]  H. Nishina,et al.  Administration of fibroblast growth factor 2 in combination with bone marrow transplantation synergistically improves carbon-tetrachloride-induced liver fibrosis in mice , 2007, Cell and Tissue Research.

[46]  M. Longaker,et al.  Gene profiling of cells expressing different FGF-2 forms. , 2005, Gene.

[47]  C. Hinojosa-Laborde,et al.  Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. , 2004, Journal of the American Society of Nephrology : JASN.

[48]  Youhua Liu.  Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. , 2004, Journal of the American Society of Nephrology : JASN.

[49]  Kumar Sharma,et al.  Diabetic kidney disease in the db/db mouse. , 2003, American journal of physiology. Renal physiology.

[50]  R. Kalluri,et al.  Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. , 2002, Kidney international.

[51]  F. Strutz,et al.  TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). , 2001, Kidney international.

[52]  M. Korc,et al.  Expression of the High Molecular Weight Fibroblast Growth Factor-2 Isoform of 210 Amino Acids Is Associated with Modulation of Protein Kinases C δ and ε and ERK Activation* , 2001, The Journal of Biological Chemistry.

[53]  F. Strutz,et al.  Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. , 2000, Kidney international.

[54]  I. Delrieu.  The high molecular weight isoforms of basic fibroblast growth factor (FGF‐2): an insight into an intracrine mechanism , 2000, FEBS letters.

[55]  D. Rifkin,et al.  Studies on FGF‐2: Nuclear localization and function of high molecular weight forms and receptor binding in the absence of heparin , 1994, Molecular reproduction and development.

[56]  H. Prats,et al.  Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor , 1991, Molecular and cellular biology.